• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
US Non-Invasive Prenatal Testing Market Outlook 2018 - Product Image

US Non-Invasive Prenatal Testing Market Outlook 2018

  • ID: 2775111
  • March 2014
  • Region: United States
  • 65 Pages
  • RNCOS E-Services Private Limited


  • Ariosa Diagnostics
  • Natera
  • Sequenom
  • Verinata
  • MORE

The average age of women giving birth in United States has increased over the years. It’s no longer unusual for women to have a first child at age 35 or even 40. This trend has been attributed to numerous factors such as recession and associated affordability issues, and women being more focused on their careers than before. However, increased age of the mother also increases the risk of her child developing chromosomal abnormalities. This risk has thus paved the way for NIPT tests which have emerged as the next big thing in the field of prenatal diagnostics.

According to our report, “US Non-Invasive Prenatal Testing Market Outlook 2018”, the rise in high risk births has been contributing to the growth of the NIPT market which is anticipated to grow at a CAGR of over 20% for the next 5 years. Our report provides a detailed insight into the current scenario and future outlook of the US NIPT. This market’s potential and the actual market have been deduced and it has been inferred that 2/3 rd of the total market remains untapped. Contribution of every NIPT player has also been provided in terms of current and future market shares.

The demographic scenario READ MORE >


  • Ariosa Diagnostics
  • Natera
  • Sequenom
  • Verinata
  • MORE

1. Analyst View

2. Research Methodology

3. Tests Available in the US NIPT Market
3.1 MaterniT21
3.2 Verifi
3.3 Panorama
3.4 Harmony

4. Current Technologies in the Market

5. Association of Down’s syndrome Risk to Fetus with Mother's Age

6. Demographics Outlook
6.1 Population Demographics
6.2 Number of Births: Current and Future
6.2.1 By Age Group
6.2.2 By State
6.3 Disease Demographics

7. US NIPT - Potential Market (2013 & 2018)

8. US NIPT Market Projections to 2018
8.1 Market Size and Forecast
8.2 Market Share of Players

9. Regulatory Insight
9.1 Current Regulatory Scenario
9.2 Regulatory Authority Perspective
9.3 Diagnostic Test Provider Perspective
9.4 ACOG Opinion
9.5 Consumers’ Perspective
9.6 Analyst Inputs

10. Reimbursement Scenario for US NIPT Market

11. Competitive Assessment
11.1 Ariosa Diagnostics
11.1.1 Business Overview
11.1.2 Strengths and Weaknesses
11.1.3 Recent Developments
11.2 Sequenom
11.2.1 Business Overview
11.2.2 Strengths and Weaknesses
11.2.3 Recent Developments
11.3 Verinata
11.3.1 Business Overview
11.3.2 Strengths and Weaknesses
11.3.3 Recent Developments
11.4 Natera
11.4.1 Business Overview
11.4.2 Strengths and Weaknesses
11.4.3 Recent Developments

List of Tables
Table 3-1: Comparison of Features of Key NIPT Tests in APAC NIPT Market
Table 3-2: MaterniT21 PLUS Test Validation Results
Table 4-1: Common Commercial Kits and Protocols for Isolation of ccff DNA from Maternal Plasma
Table 6-1: Births by Women Age-Group (%), 2010-2013
Table 6-2: Top Ten States by Number of Births (2011 & 2012)
Table 6-3: Prevalence of Chromosomal Abnormalities
Table 9-1: Inter-comparison of CLIA and FDA Regulatory Pathway
Table 10-1: Comparative Analysis of Tests Available in US NIPT Market

List of Figures
Figure 3-1: Verifi Test Validation Results
Figure 3-2: Panorma Test Validation Results
Figure 3-3: Harmony Test Validation Results
Figure 5-1: Risk of Down’s syndrome with Rise in Maternal Age
Figure 6-1: Population (Million), 2013-2018
Figure 6-2: Male- Female Ratio (%), 2013
Figure 6-3: Number of Births (Million), 2009-2013
Figure 6-4: Number of Births (Million), 2014-2018
Figure 7-1: Number of Births by Mother’s Risk of Down’s syndrome (%), 2013
Figure 7-2: High Risk NIPT Potential Market (Million US$), 2013 & 2018
Figure 7-3: Medium Risk NIPT Potential Market (Million US$), 2013 & 2018
Figure 8-1: Non-Invasive Prenatal Diagnostics Market (Million US$), 2013-2018
Figure 8-2: NIPT Market Penetration in High Risk Category (2013)
Figure 8-3: Share of Players in Number of NIPT Tests Performed (2013)
Figure 8-4: Share of Players in NIPT Market (2013)
Figure 8-5: Forecast for Share of Players in Number of NIPT Tests Performed (2018)
Figure 8-6: Forecast for Share of Players in NIPT Market (2018)
Figure 9-1: Laboratorians’ Attitudes towards FDAs Regulations on Lab Developed Tests (LDT)

- Ariosa Diagnostics
- Natera
- Sequenom
- Verinata

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos